Please assess the completion status of the following clinical trial:

Trial Title: Bone Mineral Density Changes in HIV-positive Females With Osteopenia Switching to Raltegravir

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Adult HIV-positive female patients;~* osteopenia (t-score from -1 to -2.5);~* On antiretroviral treatment with tenofovir/emtricitabine and atazanavir/ritonavir (300/100 mg) for at least six months;~* Plasma HIV RNA below 50 copies/ml since six months;~* Premenopausal women: female patients at any phase of the reproductive period with regular menstrual cycles and normal FSH (\< 25 ng/mL) That would probably exclude patients with ovarian or endocrinological dysfunctions. Pre and postmenopausal should be therefore well-characterized.~* Women in menopausal period (the menopause was defined as 12 months of amenorrhoea without any pathological or physiological cause and using the endocrinological definition of ovary insufficiency (LH (Luteic hormone) \>25ng/mL, FSH (follicule stimulating hormone)\>25ng/mL and E2 (Estradiol)\<30ng/mL).~* Each premenopausal sexually active subject of child-bearing potential must agree to use a medically accepted method of contraception while receiving protocol-specified medication and for 3 months after stopping the medication.Medically accepted methods of contraception include condoms (male or female) with or without a spermicidal agent, diaphragm or cervical cap with spermicide, medically prescribed IUD (intrauterine device), inert or copper-containing IUD, hormone-releasing IUD, systemic hormonal contraceptive, and surgical sterilization (eg, hysterectomy or tubal ligation).~* Postmenopausal women are not required to use contraception.~Exclusion Criteria:~* History or current evidence of any condition, therapy, laboratory abnormality or other circumstance that might confound the results of the study, or interfere with the patient's participation for the full duration of the study, such that it is not in the best interest of the patient to participate.~* Documented resistance to Raltegravir or/and Atazanavir.~* Patient with significant hypersensitivity or other contraindication to any of the components of the study drugs.~* Patient has a current (active) diagnosis of acute hepatitis due to any cause~* Patient with coinfection HIV/HBV (Human Hepatitis virus B)~* Liver cirrhosis~* Osteoporosis (t-score less than 2.5).~* Secondary endocrinological cause of low BMD (Bone mineral density)~* Chronic steroid intake;~* Chronic kidney disease (estimated glomerular filtration rate below 60 ml/min);~* Concomitant use of bisphosphonate.

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- raltegravir (Type: EXPERIMENTAL): raltegravir and atazanavir and ritonavir
- tenofovir/emtricitabine (Type: ACTIVE_COMPARATOR): tenofovir/emtricitabine and atazanavir and ritonavir

Based on this trial design, predict the completion outcome and termination type (if applicable).